1. Scrip
  2. >>Business

GSK Makes ADC Pipeline Comeback With Mersana Deal

Pays $100m Upfront

 
• By Ayisha Sharma

The UK major has teamed up with the US biotech to develop the latter’s HER-2 targeted antibody-drug conjugate, a couple of years after the approval of Blenrep, in what is becoming an increasingly competitive space.  

Purple Cells
GSK Already Has One ADC Product On The Market For Multiple Myeloma • Source: Shutterstock

GlaxoSmithKline Pharmaceuticals Ltd. is diving back into antibody-drug conjugate R&D with new partner Mersana Therapeutics, Inc., paying $100m upfront to develop its preclinical ADC asset for HER-2 expressing tumors.

Under the terms of the deal, GSK will acquire an exclusive option to co-develop and commercialize Mersana’s XMT-2056 which targets a novel epitope of HER2

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.